Type I coagulation factor V deficiency caused by compound heterozygous mutation of F5 gene

Haemophilia ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 646-649 ◽  
Author(s):  
Q. Fu ◽  
W. Wu ◽  
Q. Ding ◽  
Y. Hu ◽  
X. Wang ◽  
...  
Haemophilia ◽  
2006 ◽  
Vol 12 (2) ◽  
pp. 172-178 ◽  
Author(s):  
N. YAMAKAGE ◽  
M. IKEJIRI ◽  
K. OKUMURA ◽  
A. TAKAGI ◽  
T. MURATE ◽  
...  

Haematologica ◽  
2019 ◽  
Vol 105 (4) ◽  
pp. e180-e185
Author(s):  
Elvezia Maria Paraboschi ◽  
Marzia Menegatti ◽  
Valeria Rimoldi ◽  
Munira Borhany ◽  
Magy Abdelwahab ◽  
...  

2019 ◽  
Vol 47 (12) ◽  
pp. 5996-6003
Author(s):  
Yamei Zhang ◽  
Huihui Sun ◽  
Naijun Wan

Objective The aim of the study was to investigate the relationship between SLC37A4 gene mutation and clinical phenotype in a patient with glycogen storage disease-type I. Methods The clinical data of one patient with glycogen storage disease-type I accumulation syndrome and the results of SLC37A4 gene testing were analyzed. DNA from peripheral blood was used to analyze the SLC37A4 mutations of the patient and his parents. Results The patient carried a compound heterozygous mutation of SLC37A4, his mother was heterozygous for the c.572C > T (p.P191L) mutation, and his father was heterozygous for the c.359C > T (p.P120L) mutation. Conclusion The patient had two gene mutations: c.359C > T (p.P120L), which is closely related to glycogen storage disease-type I, and c.572C > T (p.P191L), which is a known mutation in the disease.


Haemophilia ◽  
2004 ◽  
Vol 10 (3) ◽  
pp. 264-270 ◽  
Author(s):  
Q.-H. Fu ◽  
R.-F. Zhou ◽  
L.-G. Liu ◽  
W.-B. Wang ◽  
W.-M. Wu ◽  
...  

2009 ◽  
Vol 20 (2) ◽  
pp. 150-156 ◽  
Author(s):  
Jaewoo Song ◽  
Ilaria Guella ◽  
Ki-Yung Kwon ◽  
Hyunsoo Cho ◽  
Rojin Park ◽  
...  

Blood ◽  
2001 ◽  
Vol 98 (2) ◽  
pp. 358-367 ◽  
Author(s):  
Richard van Wijk ◽  
Karel Nieuwenhuis ◽  
Marijke van den Berg ◽  
Eric G. Huizinga ◽  
Brenda B. van der Meijden ◽  
...  

Coagulation factor V (FV) plays an important role in maintaining the hemostatic balance in both the formation of thrombin in the procoagulant pathway as well as in the protein C anticoagulant pathway. FV deficiency is a rare bleeding disorder with variable phenotypic expression. Little is known about the molecular basis underlying this disease. This study identified 5 novel mutations associated with FV deficiency in 3 patients with severe FV deficiency but different clinical expression and 2 unaffected carriers. Four mutations led to a premature termination codon either by a nonsense mutation (single-letter amino acid codes): A1102T, K310Term. (FV Amersfoort) and C2491T, Q773Term. (FV Casablanca) or a frameshift: an 8–base pair deletion between nucleotides 1130 and 1139 (FV Seoul1) and a 1–base pair deletion between nucleotides 4291 and 4294 (FV Utrecht). One mutation was a novel missense mutation: T1927C, C585R (FV Nijkerk), resulting in the absence of mutant protein despite normal transcription to RNA. Most likely, an arginine at this position disrupts the hydrophobic interior of the FV A2 domain. The sixth detected mutation was a previously reported missense mutation: A5279G, Y1702C (FV Seoul2). In all cases, the presence of the mutation was associated with type I FV deficiency. Identifying the molecular basis of mutations underlying this rare coagulation disorder will help to obtain more insight into the mechanisms involved in the variable clinical phenotype of patients with FV deficiency.


Sign in / Sign up

Export Citation Format

Share Document